Et forsøk for å vurdere Cobicistat forsterket Venetoclax i kombinasjon med azacitidin hos voksne pasienter med nylig diagnostisert AML (HO171)
En enkeltarms fase II-forsøk for å vurdere kobicistat-forsterket venetoklaks i kombinasjon med azacitidin (sc) hos voksne pasienter med nylig diagnostisert akutt myeloid leukemi (AML) som ikke anses som kandidater for intensive behandlingsregimer
The treatment of older unfit patients with acute myeloid leukemia (AML) is challenging. The hypomethylating agents (HMA) azacitidine and decitabine have relatively mild side effects and have proven to be feasible for the treatment of older patients and patients with co-morbidities. Currently, venetoclax added to an HMA agent is the new standard of treatment. Since this new standard comes with a substantial societal financial burden, there is a rational to optimize the venetoclax dosing schedule. The CYP3A4 inhibitor cobicistat (COBI) can be used to increase venetoclax exposure, thereby allowing to reduce the dose of venetoclax and thus costs substantially.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Studietype
Studietype
Registrering (Antatt)
Registrering
Fase
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Gerwin Huls, prof
- Telefonnummer: +3150 361 2354
- E-post: g.huls@umcg.nl
Studiesteder
-
-
-
's-Hertogenbosch, Nederland
- Rekruttering
- NL-Den Bosch-JBZ
-
Ta kontakt med:
- A.H.E. Herbers, Dr.
-
Amersfoort, Nederland
- Rekruttering
- NL-Amersfoort-MEANDERMC
-
Ta kontakt med:
- M.F. Corsten, Dr.
-
Amsterdam, Nederland
- Rekruttering
- NL-Amsterdam-OLVG
-
Ta kontakt med:
- H. Mooij, Dr.
-
Amsterdam, Nederland
- Rekruttering
- NL-Amsterdam-AUMC
-
Ta kontakt med:
- C. Alhan, Dr.
-
Arnhem, Nederland
- Rekruttering
- NL-Arnhem-RIJNSTATE
-
Ta kontakt med:
- M.L.H. Cuijpers, Dr.
-
Breda, Nederland
- Rekruttering
- NL-Breda-AMPHIA
-
Ta kontakt med:
- R.B. Fiets, Dr.
-
Dordrecht, Nederland
- Rekruttering
- NL-Dordrecht-ASZ
-
Ta kontakt med:
- P.E. Westerweel, Dr.
-
Eindhoven, Nederland
- Rekruttering
- NL-Eindhoven-MAXIMAMC
-
Ta kontakt med:
- L.W. Tick, Dr.
-
Eindhoven, Nederland
- Rekruttering
- NL-Eindhoven-CATHARINA
-
Ta kontakt med:
- M.J. Cruijsen, Dr.
-
Enschede, Nederland
- Rekruttering
- NL-Enschede-MST
-
Ta kontakt med:
- T.J.F. Snijders, Dr.
-
Groningen, Nederland
- Rekruttering
- NL-Groningen-UMCG
-
Ta kontakt med:
- G.A. Huls, Prof. dr.
-
Leeuwarden, Nederland
- Rekruttering
- NL-Leeuwarden-MCL
-
Ta kontakt med:
- B. Franken, Dr.
-
Leiden, Nederland
- Rekruttering
- NL-Leiden-LUMC
-
Ta kontakt med:
- P.A. von dem Borne, Dr.
-
Maastricht, Nederland
- Rekruttering
- NL-Maastricht-MUMC
-
Ta kontakt med:
- C.H.M.J. van Elssen, Dr.
-
Nieuwegein, Nederland
- Rekruttering
- NL-Nieuwegein-ANTONIUS
-
Ta kontakt med:
- O. de Weerdt, Dr.
-
Nijmegen, Nederland
- Rekruttering
- NL-Nijmegen-RADBOUDUMC
-
Ta kontakt med:
- N.A. de Jonge, Dr.
-
Nijmegen, Nederland
- Rekruttering
- NL-Nijmegen-CWZ
-
Ta kontakt med:
- S. de Jonge, Dr.
-
The Hague, Nederland
- Rekruttering
- NL-Den Haag-HAGA
-
Ta kontakt med:
- D. van Lammeren, Dr.
-
Zwolle, Nederland
- Rekruttering
- NL-Zwolle-ISALA
-
Ta kontakt med:
- T.T. de Waal, Dr.
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
In order to be eligible to participate in this study, a patient must meet all of the following criteria:
-
Patients with: a diagnosis of AML and related precursor neoplasms according to ICC-2022 classification (excluding acute promyelocytic leukaemia) (appendix A). Patients may have had previous treatment with erythropoiesis stimulating agents (ESA) for an antecedent phase of MDS. ESAs must be stopped at least two weeks before registration.
-
Patients 18 years and older who are considered not fit for intensive chemotherapy or who decline the option of intensive chemotherapy.
-
WHO performance status 0, 1 or 2 (appendix E).
-
Leukocytes < 30 x109/L
-
Adequate renal and hepatic functions unless clearly disease related as indicated by the following laboratory values:
- Adequate renal function as demonstrated by a creatinine clearance ≥ 30 mL/min; calculated by the Cockcroft Gault formula or measured by 24 hours urine collection.
- Serum bilirubin ≤ 3 x upper limit of normal (ULN), unless considered AML-related or due to Gilbert's syndrome.
- Alanine transaminase (ALT) ≤ 3 x ULN, unless considered AML-related.
-
Male subjects who are sexually active, must agree, from Study Day 1 until at least 90 days after the last dose of study drug, to practice the protocol specified contraception. Male subjects must agree to refrain from sperm donation from initial study drug administration through at least 90 days after the last dose of study drug.
-
Female subjects must be either postmenopausal defined as: Age >55 years with no menses for ≥12 months, without an alternative medical cause. OR willing and able to use adequate contraception during and until 180 days after the last protocol treatment.
-
Written informed consent.
-
Patient is capable of giving informed consent.
-
Patient agrees not to participate in another interventional study while on treatment without approval of the (co-) Principal Investigator.
Exclusion Criteria:
A patient who meets any of the following criteria cannot be included in this study:
-
Acute promyelocytic leukemia.
-
Myelodysplastic syndrome (MDS).
-
Patients previously treated for AML or MDS (any anti-leukemic therapy including investigational agents; excluding: 1) erythropoiesis stimulating agents (ESAs); 2) hydroxyurea ((previous treatment with hydroxyurea is allowed for the control of peripheral leukemic blasts in patients with leukocytosis).
-
Diagnosis of any previous or concomitant malignancy is an exclusion criterion:
- except when the patient successfully completed treatment (chemotherapy and/or surgery and/or radiotherapy) with curative intent for this malignancy at least 24 months prior to registration;
- except for basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix.
-
Blast crisis of chronic myeloid leukemia.
-
Concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled diabetes, infection, hypertension, pulmonary disease etc.).
-
Cardiac dysfunction as defined by:
- Myocardial infarction within the last 3 months of study entry, or
- Reduced left ventricular function with an ejection fraction < 40% as measured by MUGA scan or echocardiogram, or
- Unstable angina or New York Heart Association (NYHA) grade IV congestive heart failure (see Appendix G), or
- Unstable cardiac arrhythmias.
-
History of stroke or intracranial haemorrhage within 6 months prior to registration.
-
Symptomatic central nervous system (CNS) leukemia (NO routinely lumbar puncture required to investigate CNS involvement).
-
History of non-compliance to medical regimens or considered unreliable with respect to compliance.
-
Senile dementia, mental impairment or any other psychiatric disorder that prohibits the patient from understanding and giving informed consent.
-
Current concomitant chemotherapy, radiation therapy, or immunotherapy; other than hydroxyurea.
-
Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
-
Unreplaceable use of strong inhibitors or inducers of CYP3A or CYP3A/p-GP substrates with a narrow therapeutic window (e.g. cobicistat or ritonavir for HIV treatment). Please check with Appendix I.
-
Intolerability, contra-indication or allergy to one of the study drugs.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Sekvensiell tildeling
- Masking: Ingen (Open Label)
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: single arm arm extension phase
prior to the extention phase, there is a run-in phase with (n= 20 patients of 142 total) with the same study scheme, except that cobicistat is added from cycle 2 onwards to the treatment instead of during cycle 1 |
during run-in and extention phase: from Cycle 1 until relapse during run-in and extention phase: from Cycle 1 until relapse during run-in phase: from cycle 2 until relapse during extension phase: from cycle 1 until relapse |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Pharmacokinetic equivalence of cobicistat boosted venetoclax and unboosted venetoclax (PK cycle 1 vs PK cycle 2).venetoclax and unboosted venetoclax (PK cycle 1 vs PK cycle 2).
Tidsramme: 6-8 months
|
run-in phase |
6-8 months
|
|
Overall survival (OS).
Tidsramme: 48 months
|
extension phase |
48 months
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Venetoclax and cobicistat CL, Cmax, Tmax, Cmin and AUC0-24.
Tidsramme: 6-8 months
|
run-in phase |
6-8 months
|
|
Complete remission (CR) rate defined as CR as best response during or at completion of the treatment, as determined by the Investigator, based on the European LeukemiaNet (ELN2022) recommended response criteria (see Appendix B).
Tidsramme: 48 months
|
extension phase |
48 months
|
|
CR with incomplete hematologic recovery (CRi) rate, based on the European LeukemiaNet (ELN2022) recommended response criteria (see Appendix B).
Tidsramme: 48 months
|
extension phase |
48 months
|
|
CR and CR with incomplete hematologic recovery (CRi) rate, based on the European LeukemiaNet (ELN2022) recommended response criteria (see Appendix B).
Tidsramme: 48 months
|
extension phase |
48 months
|
|
CR with partial hematologic recovery (CRh) rate, based on ELN 2022 recommendations.
Tidsramme: 48 months
|
extension phase |
48 months
|
|
CR and CR with partial hematologic recovery (CRh) rate, based on ELN 2022 recommendations.
Tidsramme: 48 months
|
extension phase |
48 months
|
|
CR or CR/CRi or CR/CRh without minimal residual disease (flow and or molecular) (CRMRD- or CR/CRiMRD- or CR/CRhMRD-).
Tidsramme: 48 months
|
extension phase |
48 months
|
|
Morphologic leukemia-free state (MLFS) rate, based on ELN2022 recommendations.
Tidsramme: 48 months
|
extension phase |
48 months
|
|
Event free survival (EFS).
Tidsramme: 48 months
|
extension phase |
48 months
|
|
Relapse-free survival (RFS).
Tidsramme: 48 months
|
extension phase |
48 months
|
|
Incidence and severity of adverse events according to CTCAE version 5.0.
Tidsramme: 48 months
|
extension phase |
48 months
|
|
Early (30-day and 60-day) mortality (in general, non-leukemic).
Tidsramme: 48 months
|
extension phase |
48 months
|
|
Time to next cycle, defined as the time from the start of the cycle until the start of the next cycle.
Tidsramme: 48 months
|
extension phase |
48 months
|
|
OS of AZA/VEN/COBI treated patients in comparison with a real-world data cohort treated during the same time period and monitored by the Dutch Cancer registry.
Tidsramme: 48 months
|
extension phase |
48 months
|
|
Prognostic/predictive impact of disease-associated genetic changes at diagnosis.
Tidsramme: 48 months
|
extension phase |
48 months
|
|
Relapse-associated genetic changes (determined at relapse). The average relative dose intensity will be computed and given by categories. The same will be done for treatment deviation.
Tidsramme: 48 months
|
extension phase |
48 months
|
|
Clonal evolution during treatment.
Tidsramme: 48 months
|
extension phase |
48 months
|
|
Exposure-response and exposure-toxicity relation of venetoclax in patients with AML.
Tidsramme: 48 months
|
extension phase |
48 months
|
|
Cost-savings on venetoclax drug costs.
Tidsramme: 48 months
|
extension phase |
48 months
|
|
Adherence to venetoclax and cobicistat.
Tidsramme: 48 months
|
extension phase |
48 months
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Neoplasmer
- Neoplasmer etter histologisk type
- Hematologiske sykdommer
- Leukemi, myeloid
- Leukemi
- Hemic og lymfatiske sykdommer
- Leukemi, Myeloid, Akutt
- Svovelforbindelser
- Organiske kjemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Thiazoles
- Azoler
- Nukleinsyrer, nukleotider og nukleosider
- Syrer, acyklisk
- Karboksylsyrer
- Cytidin
- Pyrimidin -nukleosider
- Pyrimidiner
- AZA -forbindelser
- Nukleosider
- Ribonukleosider
- Karbamater
- Kobicistat
- Azacitidin
- Venetoclax
Andre studie-ID-numre
Andre studie-ID-numre
- HO171
- 2023 (U.S. NIH-stipend/kontrakt)
- 2023-505379-61-00 (Ctis)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .